Updated ELOQUENT Data Support Elotuzumab Combination Regimen in Myeloma
Posted: Tuesday, July 23, 2019
Researchers have presented further evidence to support establishing elotuzumab plus pomalidomide and dexamethasone (EPd) as the standard of care for patients with relapsed or refractory multiple myeloma after failure of two or more prior therapies that include lenalidomide and a proteasome inhibitor. Paul G. Richardson, MD, of Dana-Farber Cancer Institute, Boston, and colleagues offered a descriptive assessment of overall survival after extended follow-up of the ELOQUENT-3 study.
At the 24th European Hematology Association (EHA) Congress in Amsterdam (Abstract PS1370), Dr. Richardson noted that after a minimum of 18.3 months of follow-up, the 12-month and 18-month progression-free survival rates were 43% and 34% for EPd and 20% and 11% for Pd, respectively. The arms initially consisted of 60 patients randomly assigned to receive EPd and 57 patients, Pd alone. “In this updated assessment after 48 (EPd: 20/60; Pd: 28/57) of the 78 (62%) deaths required for the final analysis, overall survival curves continued to diverge, with a 46% reduction in the risk of death with EPd versus Pd (hazard ratio = 0.54),” he reported.
Previously, in the primary analysis, after a minimum follow-up of 9.1 months, the researchers had reported a median progression-free survival of 10.3 months with EPd versus 4.7 months with Pd. Supported by those results, the U.S. Food and Drug Administration earlier approved EPd for the treatment of adult patients in this patient population.
Furthermore, the updated analysis of the regimen demonstrated no new safety signals for elotuzumab, an immunostimulatory monoclonal antibody that targets SLAMF7. This process “enables selective killing of multiple myeloma cells through multiple mechanisms of action and synergizes with the immunomodulatory drug pomalidomide,” Dr. Richardson and colleagues explained in the abstract.
Disclosure: The study authors’ disclosure information may be found at ehaweb.org.
